Zerion Pharma has announced that one of its partners has submitted a marketing authorisation application in several European countries for a medicinal product formulated with the company’s Dispersome technology.
It is the first regulatory submission worldwide for a product incorporating the platform, which uses beta‑lactoglobulin to improve the solubility and bioavailability of poorly soluble small‑molecule drugs.
The filing follows Zerion’s 2026 transaction with Ligand Pharmaceuticals, which provided funding to advance Dispersome technology and support regulatory review of the first product using the approach.
Ole Wiborg, Chief Executive Officer of Zerion Pharma, said: “I was more than delighted to learn that the application had been submitted. This represents one of the most significant milestones in ZERION´s history and brings us an important step closer to our goal of achieving the first regulatory approval for a product incorporating our Dispersome technology.” He added: “We now look forward to the regulatory review of the application and the assessment of BLG as a novel excipient.”
The European submission will allow regulators to evaluate BLG’s use as a new excipient. Subject to approval and commercial launch, Zerion will receive royalties on product sales.
Dispersome technology offers an alternative approach for oral and pulmonary delivery of poorly soluble drugs. By using BLG as a carrier, it enables stable amorphous drug‑delivery systems with high drug loading. Depending on the compound, this may reduce active ingredient requirements, decrease tablet burden and cut manufacturing waste.
Zerion said the performance of Dispersome formulations has been demonstrated in multiple preclinical and clinical studies.
